← 홈

전체 프로그램

ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-8 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 3,526개
ADCBiologicstaleNYU Langone HealthPhase 2

Leflunomide (Leflunomide)

Rheumatic Disease · Takayasu Arteritis

#TakayasuArteritis#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 6.35%임상시험 59상태 RECRUITING
CGTBiologicstaleImmunityBio, Inc.sPhase 2

Activated NK Cells (M-CENK, M-CENK (Activated NK Cells))

High-risk Prostate Cancer · High-risk Prostate Cancer

#High-riskProstateCancer#CGT#Phase2#인기#세포유전치료+4
임상시험 59상태 DISCONTINUED
CGTBiologicSarah WeissPhase 1

Naltrexone (Naltrexone)

Advanced Melanoma · Advanced Melanoma

#AdvancedMelanoma#CGT#Phase1#인기#세포유전치료+3
효능 ORR 6.6%임상시험 59상태 RECRUITING
ADCBiologicNanogen Pharmaceutical Biotechn…Phase 2

Neulasta (Neulasta)

Hodgkin Lymphoma; Anaplastic Large Cell Lymphoma · Hodgkin Lymphoma

#HodgkinLymphoma#ADC#Phase2#인기#항체약물접합체+3
효능 ORR 64%임상시험 59상태 ACTIVE
CGTBiologicstaleBinhui Biopharmaceutical Co., L…Phase 1

IDOV-SAFETM (Oncolytic Virus injection, Oncolytic Virus injection(IDOV-SAFETM))

Neoplasms · Neoplasms

#Neoplasms#CGT#Phase1#인기#세포유전치료+4
효능 ORR 28%임상시험 59상태 RECRUITING
ADCBiologicAtreca, Inc.vedotin (BV), an anti-CD30 …Preclinical

PD-1 and PD-L1 inhibitor (PD-1 and PD-L1 inhibitor)

Immune-related Adverse Event; Malignant Solid Tumors · PD-1

#PD-1#ADC#Preclinical#인기#항체약물접합체+5
효능 ORR 59%임상시험 59상태 RECRUITING
CGTBiologicstaleInge Marie SvanePhase 1

Proleukin (Proleukin)

Melanoma Stage III; Melanoma Stage IV · Melanoma Stage III

#MelanomaStageIII#CGT#Phase1#인기#세포유전치료+5
효능 ORR 33.3%임상시험 59상태 RECRUITING
CGTBiologicstaleSPP Pharmaclon Ltd.Phase 2

Recombinant Interferon Alfa (Recombinant Interferon Alfa)

Colorectal Cancer; Kidney Cancer · Bladder Cancer

#BladderCancer#CGT#Phase2#인기#세포유전치료+5
효능 ORR 32.4%임상시험 59상태 ACTIVE
ADCBiologicstaleGenzyme, a Sanofi Companyvedotin-based regimens in C…Phase 2

Reduced Intensity Conditioning (Reduced Intensity Conditioning)

Hodgkin Lymphoma · Hodgkin Lymphoma

#HodgkinLymphoma#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 2%임상시험 59상태 ACTIVE
ADCBiologicstaleRocheDM1 via butelase-1 with ABD…Phase 3

T-DM1 (Trastuzumab emtansine, Trastuzumab emtansine (T-DM1))

Advanced Breast Cancer; Objective Response Rate · HER2

#HER2#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 69.7%임상시험 59상태 RECRUITING
ADCBiologicstaleHoffmann-La RochePhase 2

Vismodegib (Vismodegib)

Cancer of Unknown Primary Site · FRα

#FR#ADC#Phase2#인기#항체약물접합체+3
효능 ORR 88%임상시험 59상태 DISCONTINUED
CGTBiologicstaleSMT bio Co., Ltd.Phase 2

allogeneic Natural Killer cell ('SMT-NK' Inj, 'SMT-NK' Inj (allogeneic Natural Killer cell))

Biliary Tract Cancer · Biliary Tract Cancer

#BiliaryTractCancer#CGT#Phase2#인기#세포유전치료+4
효능 ORR 42%임상시험 58상태 ACTIVE
CGTAAVBiologicstaleBayerPhase 1

AAVrh.10hFXN, serotype rh.10 adeno-associated virus (AAV, AAVrh.10hFXN, serotype rh.10 adeno-associated virus, AAVrh.10hFXN, serotype rh.10 adeno-associated virus (AAV) gene transfer vector expressing the cDNA coding for human FXN)

Friedreich Ataxia; Cardiomyopathies · Friedreich Ataxia

#FriedreichAtaxia#CGT#Phase1#인기#세포유전치료+5
효능 ORR 11.9%임상시험 58상태 RECRUITING
CGTBiologicstalePaolo Caimi, MDPhase 1

Allogeneic NK cells (Allogeneic NK cells)

Non Hodgkin Lymphoma; B-cell Non Hodgkin Lymphoma · Non Hodgkin Lymphoma

#NonHodgkinLymphoma#CGT#Phase1#인기#세포유전치료+4
효능 ORR 5%임상시험 58상태 RECRUITING
ADCBiologicstaleFavrillederuxtecan for metastatic b…Phase 2

Antibody-Drug Conjugate Therapy (Antibody-Drug Conjugate Therapy)

Metastatic Bladder Urothelial Carcinoma; Metastatic Renal Pelvis and Ureter Urothelial Carcinoma · FRα

#FR#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 86%임상시험 58상태 RECRUITING
ADCBiologicstaleJanssen Research & Development,…Phase 1

Apalutamide (Apalutamide)

Prostatic Neoplasms · Metastatic Prostate Cancer

#MetastaticProstateCancer#ADC#Phase1#인기#항체약물접합체+3
효능 ORR 2.6%임상시험 58상태 RECRUITING
AntibodystaleRochePhase 2

atezolizumab (Tecentriq, Atezolizumab and Bevacizumab)

Hepatocellular Carcinoma · Resectable Hepatocellular Carcinoma

#ResectableHepatocellularCarcinom#Antibody#Phase2#인기#항체+5
효능 ORR 50%임상시험 58상태 DISCONTINUED
AntibodystaleNovartisApproved

Basiliximab (Basiliximab)

Type 1 Diabetes Mellitus · Extranodal NK/T-cell Lymphoma

#ExtranodalNKT-cellLymphoma#Antibody#Approved#인기#항체+4
효능 ORR 10%임상시험 58상태 ACTIVE
CGTBiologicstaleLion TCR Pte. Ltd.Phase 1

Biological: TCR-T (Biological: TCR-T)

Recurrent Hepatocellular Carcinoma · Recurrent Hepatocellular Carcinoma

#RecurrentHepatocellularCarcinoma#CGT#Phase1#인기#세포유전치료+4
효능 ORR 11.8%임상시험 58상태 ACTIVE
CGTBiologicstaleNovartis PharmaceuticalsPhase 2

Bridging Therapy (Bridging Therapy)

Non-Hodgkin Lymphoma · Non-Hodgkin Lymphoma

#Non-HodgkinLymphoma#CGT#Phase2#인기#세포유전치료+4
효능 ORR 32.1%임상시험 58상태 DISCONTINUED

17 / 177 페이지

← 이전다음 →